CDXC Insider Trading

Insider Ownership Percentage: 9.64%
Insider Buying (Last 12 Months): $21,395.52
Insider Selling (Last 12 Months): $312,136.59

ChromaDex Insider Trading History Chart

This chart shows the insider buying and selling history at ChromaDex by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

ChromaDex Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 03/18/2025 08:53 PM ET

This chart shows the closing price history over time for CDXC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$7.87Closing price on 03/19/25:

ChromaDex Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for ChromaDex (NASDAQ:CDXC)

15.41% of ChromaDex stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CDXC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
ChromaDex logo
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Read More on ChromaDex

Today's Range

Now: N/A

50 Day Range

MA: $6.16
Low: $5.26
High: $8.55

52 Week Range

Now: N/A

Volume

554,788 shs

Average Volume

727,901 shs

Market Capitalization

$611.50 million

P/E Ratio

787.29

Dividend Yield

N/A

Beta

2.21

Who are the company insiders with the largest holdings of ChromaDex?

ChromaDex's top insider shareholders include:
  1. Frank L Jaksch Jr (Director)
  2. Robert N Fried (CEO)
  3. Brianna Gerber (CFO)
  4. Steven D Rubin (Director)
  5. Ozan Pamir (CFO)
  6. Kristin Patrick (Director)
Learn More about top insider investors at ChromaDex.